Immunovant annual shares outstanding
2019
2020
2021
2022
2023
2024
2025
2026
Immunovant Shares Outstanding History (IMVT)
Immunovant reported 203.9M shares outstanding at the end of fiscal 2026.
View full Immunovant company overviewImmunovant annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-03-31 | 203.9M | 33.8M | +19.89% |
| 2025 | 2025-03-31 | 170.1M | 24.5M | +16.85% |
| 2024 | 2024-03-31 | 145.6M | 15.3M | +11.70% |
| 2023 | 2023-03-31 | 130.3M | 13.8M | +11.89% |
| 2022 | 2022-03-31 | 116.5M | 18.5M | +18.89% |
| 2021 | 2021-03-31 | 98.0M | 43.3M | +79.25% |
| 2020 | 2020-03-31 | 54.7M | 16.1M | +41.63% |
| 2019 | 2019-03-31 | 38.6M | — | — |
Immunovant quarterly shares outstanding
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
Q1.27
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q1 2027 | 2026-06-30 | 206.3M | 35.2M | +20.57% |
| Q4 2026 | 2026-03-31 | 203.9M | 33.8M | +19.89% |
| Q3 2026 | 2025-12-31 | 203.3M | 56.1M | +38.12% |
| Q2 2026 | 2025-09-30 | 174.5M | 28.0M | +19.08% |
| Q1 2026 | 2025-06-30 | 171.1M | 24.9M | +17.01% |
| Q4 2025 | 2025-03-31 | 170.1M | 24.5M | +16.85% |
| Q3 2025 | 2024-12-31 | 147.2M | 2.1M | +1.45% |
| Q2 2025 | 2024-09-30 | 146.6M | 15.1M | +11.51% |
| Q1 2025 | 2024-06-30 | 146.2M | 15.6M | +11.97% |
| Q4 2024 | 2024-03-31 | 145.6M | 15.3M | +11.70% |
| Q3 2024 | 2023-12-31 | 145.1M | 15.8M | +12.25% |
| Q2 2024 | 2023-09-30 | 131.4M | 14.8M | +12.72% |
| Q1 2024 | 2023-06-30 | 130.6M | 14.0M | +12.05% |
| Q4 2023 | 2023-03-31 | 130.3M | 13.8M | +11.89% |
| Q3 2023 | 2022-12-31 | 129.3M | 14.2M | +12.29% |
| Q2 2023 | 2022-09-30 | 116.6M | 1.6M | +1.40% |
| Q1 2023 | 2022-06-30 | 116.5M | 18.5M | +18.93% |
| Q4 2022 | 2022-03-31 | 116.5M | 18.5M | +18.89% |
| Q3 2022 | 2021-12-31 | 115.1M | 17.1M | +17.49% |
| Q2 2022 | 2021-09-30 | 115.0M | 17.1M | +17.48% |
| Q1 2022 | 2021-06-30 | 98.0M | 17.1M | +21.09% |
| Q4 2021 | 2021-03-31 | 98.0M | 43.3M | +79.25% |
| Q3 2021 | 2020-12-31 | 98.0M | 43.3M | +79.25% |
| Q2 2021 | 2020-09-30 | 97.9M | 94.4M | +2671.11% |
| Q1 2021 | 2020-06-30 | 80.9M | 77.4M | +2182.38% |
| Q4 2020 | 2020-03-31 | 54.7M | 51.8M | +1801.06% |
| Q3 2020 | 2019-12-31 | 54.7M | 51.8M | +1801.06% |
| Q2 2020 | 2019-09-30 | 3.5M | — | — |
| Q1 2020 | 2019-06-30 | 3.5M | — | — |
| Q4 2019 | 2019-03-31 | 2.9M | — | — |
| Q3 2019 | 2018-12-31 | 2.9M | — | — |
Immunovant shares outstanding trends
Over the last five reported fiscal years, Immunovant's shares outstanding moved from 98.0M to 203.9M, a change of 106.0M. The latest reported quarter, Q1 2027, shows 206.3M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immunovant filings at SEC.gov ↗